Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 10;13(3):e066995.
doi: 10.1136/bmjopen-2022-066995.

Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial

Edward Tang Qian  1 , Jonathan D Casey  2 , Adam Wright  3 , Li Wang  4 , Justin Siemann  5 , Mary Lynn Dear  5 , Joanna Stollings  6 , Bradley Daniel Lloyd  7 , Kevin Seitz  2 , George Nelson  8 , Patty Wright  8 , Edward D Siew  9 , Bradley Dennis  10 , Jesse Wrenn  7 , Jonathan Andereck  7 , Wesley H Self  7 , Matthew W Semler #  2 , Todd W Rice #  2 ; Vanderbilt Learning Healthcare System Platform Investigators
Collaborators, Affiliations

Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial

Edward Tang Qian et al. BMJ Open. .

Abstract

Introduction: Antibiotics are time-critical in the management of sepsis. When infectious organisms are unknown, patients are treated with empiric antibiotics to include coverage for gram-negative organisms, such as antipseudomonal cephalosporins and penicillins. However, in observational studies, some antipseudomonal cephalosporins (eg, cefepime) are associated with neurologic dysfunction while the most common antipseudomonal penicillin (piperacillin-tazobactam) is associated with acute kidney injury (AKI). No randomised control trials have compared these regimens. This manuscript describes the protocol and analysis plan for a trial designed to compare the effects of antipseudomonal cephalosporins and antipseudomonal penicillins among acutely ill patients receiving empiric antibiotics.

Methods and analysis: The Antibiotic Choice On ReNal outcomes trial is a prospective, single-centre, non-blinded randomised trial being conducted at Vanderbilt University Medical Center. The trial will enrol 2500 acutely ill adults receiving gram-negative coverage for treatment of infection. Eligible patients are randomised 1:1 to receive cefepime or piperacillin-tazobactam on first order entry of a broad-spectrum antibiotic covering gram-negative organisms. The primary outcome is the highest stage of AKI and death occurring between enrolment and 14 days after enrolment. This will be compared between patients randomised to cefepime and randomised to piperacillin-tazobactam using an unadjusted proportional odds regression model. The secondary outcomes are major adverse kidney events through day 14 and number of days alive and free of delirium and coma in 14 days after enrolment. Enrolment began on 10 November 2021 and is expected to be completed in December 2022.

Ethics and dissemination: The trial was approved by the Vanderbilt University Medical Center institutional review board (IRB#210591) with a waiver of informed consent. Results will be submitted to a peer-reviewed journal and presented at scientific conferences.

Trial registration number: NCT05094154.

Keywords: Adult intensive & critical care; INFECTIOUS DISEASES; Nephrology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Electronic health record-based enrolment advisor. ACORN, Antibiotic Choice On ReNal outcomes. D5W - Dextrose 5% in Water; IVPB - Intravenous Piggyback; PCN - penicillin
See this image and copyright information in PMC

References

    1. Rhodes A, Evans LE, Alhazzani W, et al. . Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304–77. 10.1007/s00134-017-4683-6 - DOI - PubMed
    1. Wright J, Paauw DS. Complications of antibiotic therapy. Med Clin North Am 2013;97:667–79. 10.1016/j.mcna.2013.02.006 - DOI - PubMed
    1. Chanderraj R, Baker JM, Kay SG, et al. . In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes. Eur Respir J 2023;61:2200910. 10.1183/13993003.00910-2022 - DOI - PMC - PubMed
    1. Finfer S, Micallef S, Hammond N, et al. . Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med 2022;386:815–26. 10.1056/NEJMoa2114464 - DOI - PubMed
    1. Kim PW, Wu Y, Cooper C, et al. . Meta-Analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010;51:381–9. 10.1086/655131 - DOI - PubMed

Publication types

Associated data